Mega Genomics’ HK$215 Million IPO

Paul Hastings advised Mega Genomics Limited on the deal while Sidley represented China Securities.

Mega Genomics Limited, the largest consumer genetic testing platform in China in terms of the cumulative number of tests administered, announced its HK$215 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange. China Securities (International) Corporate Finance Company Limited acted as the sole sponsor for this transaction.

Mega Genomics Limited is a leading full-spectrum genetic testing platform in China for consumer genetic testing, cancer screening, nutrition and metabolism, chronic disease susceptibility, and pharmacogenetic and infectious disease testing.

With an industry-leading expertise in Hong Kong capital markets, Paul Hastings has advised on some of the most representative biotech and healthcare companies in their listings in Hong Kong in recent years, including a biopharmaceutical company SciClone Pharmaceutical, a Hong Kong-based biopharmaceutical company SinoMab BioScience Limited (listed under Chapter 18A), an assisted reproductive services company Jinxin Fertility Group, a Chinese vaccine company CanSino Biologics Inc. and a Chinese biotech company Ascletis Pharma (the first listing under Chapter 18A).

The Paul Hastings team was led by Jia Yan (Picture) and David Wang, co-chairs of the firm’s mainland China offices, and Corporate partner Samuel Ng, with support from associates Devin Geng, Nancy Sun, Stefan Chan and Stephen Chow, China associates Lanxin Zhang and Julia Hu, and China advisor Yanqiu Yang.

The Sidley team was led by partners Claudia Yu and Meng Ding. Key team members included registered foreign lawyer Dennis Chan, associate Cindy Liu, and senior legal assistants Jiangyuan Song and Sia Yang. Associate Gary Wu, senior legal assistant Alice Liu, and scientific adviser Xiaotong Yang also provided assistance.

Involved fees earner: Stefan Chan – Paul Hastings LLP; Stephen Chow – Paul Hastings LLP; Devin Geng – Paul Hastings LLP; Julia Hu – Paul Hastings LLP; Samuel Ng – Paul Hastings LLP; Nancy Sun – Paul Hastings LLP; David Wang – Paul Hastings LLP; Jia Yan – Paul Hastings LLP; Lanxin Zhang – Paul Hastings LLP; Meng Ding – Sidley Austin LLP; Claudia Yu – Sidley Austin LLP;

Law Firms: Paul Hastings LLP; Sidley Austin LLP;

Clients: China Securities (International) Finance; Mega Genomics Limited;

Martina Bellini

Author: Martina Bellini